Literature DB >> 23849924

Under-reporting of adverse effects of tesofensine.

Arne Astrup, Sten Madsbad, Leif Breum, Thomas J Jensen, Jens P Kroustrup, Thomas M Larsen.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23849924     DOI： 10.1016/S0140-6736(13)61563-9

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  3 in total

Review 1.  Anorectic state of obesity medications in the United States. Are leaner times ahead?

Authors:  Xinyi Li; Nicholas T Bello
Journal:  Expert Opin Pharmacother       Date:  2019-11-24       Impact factor: 3.889

Review 2.  New targets to treat obesity and the metabolic syndrome.

Authors:  Kathleen A Martin; Mitra V Mani; Arya Mani
Journal:  Eur J Pharmacol       Date:  2015-05-19       Impact factor: 4.432

3.  Randomized controlled trial of Tesomet for weight loss in hypothalamic obesity.

Authors:  Kim Huynh; Marianne Klose; Kim Krogsgaard; Jørgen Drejer; Sarah Byberg; Sten Madsbad; Faidon Magkos; Abdellatif Aharaz; Berit Edsberg; Jacob Tfelt-Hansen; Arne Vernon Astrup; Ulla Feldt-Rasmussen
Journal:  Eur J Endocrinol       Date:  2022-05-09       Impact factor: 6.558
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.